 BALA CYNWYD, Pa., May 25, 2021 GLOBE NEWSWIRE -- Larimar Therapeutics, Inc. Larimar Nasdaq: LRMR, a clinical-stage biotechnology company focused on developing treatments for Friedreichs ataxia FA and other complex rare diseases, today announced that the United States Food and Drug Administration FDA has placed a clinical hold on the CTI-1601 clinical program and that the company will not be closing a previously announced private placement financing. CTI-1601 is a recombinant fusion protein intended to deliver human frataxin into the mitochondria of patients with FA who are unable to produce enough of this essential protein. 